Literature DB >> 21364698

Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland.

Tiina Suominen1, Linda L Bachinski, Satu Auvinen, Peter Hackman, Keith A Baggerly, Corrado Angelini, Leena Peltonen, Ralf Krahe, Bjarne Udd.   

Abstract

Myotonic dystrophy (DM) is the most common adult-onset muscular dystrophy with an estimated prevalence of 1/8000. There are two genetically distinct types, DM1 and DM2. DM2 is generally milder with more phenotypic variability than the classic DM1. Our previous data on co-segregation of heterozygous recessive CLCN1 mutations in DM2 patients indicated a higher than expected DM2 prevalence. The aim of this study was to determine the DM2 and DM1 frequency in the general population, and to explore whether the DM2 mutation functions as a modifier in other neuromuscular diseases (NMD) to account for unexplained phenotypic variability. We genotyped 5535 Finnish individuals: 4532 normal blood donors, 606 patients with various non-myotonic NMD, 221 tibial muscular dystrophy patients and their 176 healthy relatives for the DM2 and DM1 mutations. We also genotyped an Italian idiopathic non-myotonic proximal myopathy cohort (n = 93) for the DM2 mutation. In 5496 samples analyzed for DM2, we found three DM2 mutations and two premutations. In 5511 samples analyzed for DM1, we found two DM1 mutations and two premutations. In the Italian cohort, we identified one patient with a DM2 mutation. We conclude that the DM2 mutation frequency is significantly higher in the general population (1/1830; P-value = 0.0326) than previously estimated. The identification of DM2 mutations in NMD patients with clinical phenotypes not previously associated with DM2 is of particular interest and is in accord with the high overall prevalence. On the basis of our results, DM2 appears more frequent than DM1, with most DM2 patients currently undiagnosed with symptoms frequently occurring in the elderly population.

Entities:  

Mesh:

Year:  2011        PMID: 21364698      PMCID: PMC3137497          DOI: 10.1038/ejhg.2011.23

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  29 in total

1.  Microsatellite instability (MSI) increases with age in normal somatic cells.

Authors:  Mary I Coolbaugh-Murphy; Jingping Xu; Louis S Ramagli; Barry W Brown; Michael J Siciliano
Journal:  Mech Ageing Dev       Date:  2005-10       Impact factor: 5.432

2.  High frequency of co-segregating CLCN1 mutations among myotonic dystrophy type 2 patients from Finland and Germany.

Authors:  T Suominen; B Schoser; O Raheem; S Auvinen; M Walter; R Krahe; H Lochmüller; W Kress; B Udd
Journal:  J Neurol       Date:  2008-09-24       Impact factor: 4.849

3.  Titinopathies and extension of the M-line mutation phenotype beyond distal myopathy and LGMD2J.

Authors:  B Udd; A Vihola; J Sarparanta; I Richard; P Hackman
Journal:  Neurology       Date:  2005-02-22       Impact factor: 9.910

Review 4.  Clinical and molecular aspects of the myotonic dystrophies: a review.

Authors:  Laura Machuca-Tzili; David Brook; David Hilton-Jones
Journal:  Muscle Nerve       Date:  2005-07       Impact factor: 3.217

5.  Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9.

Authors:  C L Liquori; K Ricker; M L Moseley; J F Jacobsen; W Kress; S L Naylor; J W Day; L P Ranum
Journal:  Science       Date:  2001-08-03       Impact factor: 47.728

Review 6.  Sudden cardiac death in myotonic dystrophy type 2.

Authors:  B G H Schoser; K Ricker; C Schneider-Gold; C Hengstenberg; J Dürre; B Bültmann; W Kress; J W Day; L P W Ranum
Journal:  Neurology       Date:  2004-12-28       Impact factor: 9.910

7.  Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum.

Authors:  J W Day; K Ricker; J F Jacobsen; L J Rasmussen; K A Dick; W Kress; C Schneider; M C Koch; G J Beilman; A R Harrison; J C Dalton; L P W Ranum
Journal:  Neurology       Date:  2003-02-25       Impact factor: 9.910

8.  Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect.

Authors:  Linda L Bachinski; Bjarne Udd; Giovanni Meola; Valeria Sansone; Guillaume Bassez; Bruno Eymard; Charles A Thornton; Richard T Moxley; Peter S Harper; Mark T Rogers; Karin Jurkat-Rott; Frank Lehmann-Horn; Thomas Wieser; Josep Gamez; Carmen Navarro; Armand Bottani; Andre Kohler; Mark D Shriver; Riitta Sallinen; Maija Wessman; Shanxiang Zhang; Fred A Wright; Ralf Krahe
Journal:  Am J Hum Genet       Date:  2003-09-10       Impact factor: 11.025

9.  Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene.

Authors:  M Mahadevan; C Tsilfidis; L Sabourin; G Shutler; C Amemiya; G Jansen; C Neville; M Narang; J Barceló; K O'Hoy
Journal:  Science       Date:  1992-03-06       Impact factor: 47.728

10.  Prevalence of myotonic dystrophy in Israeli Jewish communities: inter-community variation and founder premutations.

Authors:  Reeval Segel; Shira Silverstein; Israela Lerer; Esther Kahana; Rachel Meir; Michal Sagi; Nelly Zilber; Amos D Korczyn; Yehuda Shapira; Zohar Argov; Dvorah Abeliovich
Journal:  Am J Med Genet A       Date:  2003-06-15       Impact factor: 2.802

View more
  44 in total

1.  Cancer risk among patients with myotonic muscular dystrophy.

Authors:  Shahinaz M Gadalla; Marie Lund; Ruth M Pfeiffer; Sanne Gørtz; Christine M Mueller; Richard T Moxley; Sigurdur Y Kristinsson; Magnus Björkholm; Fatma M Shebl; James E Hilbert; Ola Landgren; Jan Wohlfahrt; Mads Melbye; Mark H Greene
Journal:  JAMA       Date:  2011-12-14       Impact factor: 56.272

2.  Diagnostic odyssey of patients with myotonic dystrophy.

Authors:  James E Hilbert; Tetsuo Ashizawa; John W Day; Elizabeth A Luebbe; William B Martens; Michael P McDermott; Rabi Tawil; Charles A Thornton; Richard T Moxley
Journal:  J Neurol       Date:  2013-06-27       Impact factor: 4.849

3.  Assessing the influence of age and gender on the phenotype of myotonic dystrophy type 2.

Authors:  Federica Montagnese; Stefania Mondello; Stephan Wenninger; Wolfram Kress; Benedikt Schoser
Journal:  J Neurol       Date:  2017-10-30       Impact factor: 4.849

4.  Relative risks for comorbidities associated with myotonic dystrophy: A population-based analysis.

Authors:  Nicholas E Johnson; Diana Abbott; Lisa A Cannon-Albright
Journal:  Muscle Nerve       Date:  2015-08-26       Impact factor: 3.217

Review 5.  Myotonic dystrophy mouse models: towards rational therapy development.

Authors:  Mário Gomes-Pereira; Thomas A Cooper; Geneviève Gourdon
Journal:  Trends Mol Med       Date:  2011-07-02       Impact factor: 11.951

6.  Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy.

Authors:  Bryan P Fitzgerald; Kelly M Conn; Joanne Smith; Andrew Walker; Amy L Parkhill; James E Hilbert; Elizabeth A Luebbe; Richard T Moxley
Journal:  J Neurol       Date:  2016-10-12       Impact factor: 4.849

Review 7.  Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.

Authors:  Giovanni Meola; Rosanna Cardani
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

Review 8.  Myotonic dystrophy.

Authors:  Charles A Thornton
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

Review 9.  Recent advances in myotonic dystrophy type 2.

Authors:  Christina M Ulane; Sarah Teed; Jacinda Sampson
Journal:  Curr Neurol Neurosci Rep       Date:  2014-02       Impact factor: 5.081

10.  Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the U.K. Clinical Practice Research Datalink.

Authors:  Youjin Wang; Ruth M Pfeiffer; Rotana Alsaggaf; Wilhelmine Meeraus; Julia C Gage; Lesley A Anderson; Renée C Bremer; Nikoletta Nikolenko; Hanns Lochmuller; Mark H Greene; Shahinaz M Gadalla
Journal:  Int J Cancer       Date:  2017-11-20       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.